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ABSTRACT
Metastasis is a major cause of mortality for cancer patients and remains as the 
greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not 
be controlled by the inhibition of single target. This study was aimed at assessing the 
hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and 
protein molecules to achieve “saturation attack” against metastasis. Independent 
actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR-
34a and protein-inhibiting sorafenib on DNA replication, RNA translation and 
protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were 
demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression 
and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were 
found for triple-drug combination. Consequently, triple-drug treatment showed a 
strong synergism in suppressing 143B cell proliferation and the greatest effects in 
reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug 
therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression 
to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous 
metastases mouse models, while none showed significant toxicity. In addition, triple-
drug therapy improved the overall survival to the greatest extent in experimental 
metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and 
protein molecules as a novel therapeutic strategy for the treatment of metastasis.
INTRODUCTION
Metastasis remains a major cause of death of 
cancer patients. Approximately 90% of cancer-associated 
mortality arises from systemic metastasis of the primary 
tumor [1-3]. As an example, osteosarcoma (OS), a primary 
locally destructive mesenchymal tumor accounting for 
60% of malignant bone tumors among children and 
young adults, has a predilection for lung metastases [4-
6]. Improved therapies for OS have increased the 5-year 
survival rate to 60-70% for non-metastatic OS of the 
extremities [7-9], dramatically extending the life span of 
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childhood OS survivors. However, the 5-years survival 
rate is only 18-33% for those with lung metastases at the 
time of diagnosis [9-11]. Overall 80% of OS patients die 
from distant metastases, most commonly in the lungs [9].
The processes such as invasion from the primary 
site, circulation of tumor-initiating cells, metastatic 
colonization, and distant outgrowth of metastases 
underlying cancer invasion-metastasis cascade are very 
complex [1-3]. While some molecular determinants 
and signaling pathways (e.g., c-MET, VEGF, Ras-Raf-
MAPK-ERK pathways, etc.) behind cancer metastatic 
processes have been identified, much remains poorly 
understood. Furthermore, the presence of redundant 
signaling pathways and the emergence of complementary 
mechanisms and resistant phenotypes limit the efficacy of 
targeted anti-neoplastic therapies. Therefore, combating 
metastasis remains one of the greatest challenges in cancer 
therapy [3, 12] and blocking single target or pathway is 
unlikely to be very effective.
We recently established a novel platform for high-
yield production of biologic RNA-interfering (RNAi) 
agents including miRNAs and siRNAs [13, 14] that are 
distinguished from commonly used synthetic RNAi 
reagents carrying extensive artificial modifications [15]. 
We also demonstrated that biologic miR-34a prodrug was 
precisely processed to mature miR-34a and thus effective 
to regulate target gene expression (e.g., c-MET) [14, 16]. 
In addition, combination therapy with miR-34a prodrug 
and doxorubicin exerted synergistic effects in repressing 
human OS cell growth via RNA interference and DNA 
intercalation, and this combination is more effective than 
monotherapy in suppressing OS xenograft tumor growth 
[17]. 
To explore new strategy for the treatment of 
metastasis, we hypothesized that optimal outcomes 
might be achieved through “saturation attack”, i.e., 
co-targeting of DNA, and particular RNA and protein 
molecules (Figure 1A) critical for almost all cancer 
cellular processes. To test the hypothesis, we employed 
DNA-intercalating doxorubicin, RNA-interfering miR-
34a, and protein kinase-inhibiting sorafenib as model 
drugs and assessed their independent and complementary 
actions in highly metastatic, human OS 143B model cells. 
Doxorubicin is one of the chemotherapeutic agents (i.e., 
methotrexate, doxorubicin, and cisplatin; sometimes with 
ifosfamide) that are currently used for the treatment of 
soft tissue sarcomas [7]. Since VEGFR and Raf/MEK/
ERK signaling pathways have been reported to be relevant 
to OS progression [18-20], sorafenib was chosen as a 
protein kinase-inhibiting model drug. Because miR-34a 
is significantly downregulated in human OS tissues [18, 
19] and reintroduction of miR-34a into OS cells inhibits 
cell proliferation and suppresses tumorigenesis [20, 21], 
miR-34a was selected as an RNA-interfering agent. In 
addition, the biologic miR-34a prodrug used in this study 
was produced and folded in live cells [13, 14], which 
is distinguished from synthetic miRNA agents bearing 
extensive artificial modifications [15, 22]. As a result, 
the combined drugs showed a strong synergism and the 
greatest effects in suppressing OS cell proliferation and 
invasion. In spontaneous and experimental metastasis 
mouse models, rational triple-drug combination therapy 
elicited the most beneficial outcomes, as manifested 
by the highest degrees of suppression of orthotopic 
OS progression and pulmonary metastases, as well as 
improvement of survival. 
RESULTS
Independent and combined actions of 
doxorubicin, sorafenib and miR-34a on target 
molecules in metastatic 143B cells
To test the concept of co-targeting of critical DNA, 
RNA and protein molecules in metastatic cancer cells 
(Figure 1A), we first examined the effects of model drugs 
doxorubicin, miR-34a and sorafenib on corresponding 
targets and marker proteins in OS 143B cells and 
defined their interactions when used in combination. An 
immunofluorescent study was carried out to investigate 
γH2A.X foci formation, which is a sensitive and robust 
biomarker of DNA damage [23] induced by DNA-
intercalating drugs and may indicate the mechanistic 
actions of doxorubicin. Compared to 143B cells treated 
with vehicle, sorafenib plus miR-34a treatment did 
not alter γH2A.X signal intensity while doxorubicin 
alone sharply induced the damage of DNA (Figure 1B). 
Moreover, co-administration of sorafenib and miR-34a, 
alone or together, with doxorubicin sharply increased 
the levels of γH2A.X. The highest levels were observed 
in cells treated with doxorubicin plus miR-34a, with or 
without sorafenib (Figure 1B). The same results were 
obtained by Western blot analyses of γH2A.X (data not 
shown), indicating that sorafenib or miR-34a alone or 
combined does not alter γH2A.X foci formation but is able 
to largely enhance doxorubicin-provoked DNA damage in 
143B cells.
Western blots were performed to verify the effects 
of miR-34a and sorafenib as well as combinatorial 
effects in 143B cells (Figure 1C). Compared to vehicle 
treatment, miR-34a led to a 40% suppression of c-MET 
protein levels, a well-defined miR-34a target [24-26] 
being involved in osteosarcoma metastasis [27-29]. To 
our surprise, either doxorubicin or sorafenib alone or in 
combination led to an upregulation of c-MET. However, 
co-administration of miR-34a abrogated the increase of 
c-MET expression caused by doxorubicin and sorafenib 
(Figure 1C). Likewise, the inhibitory effects of sorafenib 
on protein kinases [30-32] were indicated by an 80% 
reduction in phosphorylation of target Erk1/2, as revealed 
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by Western blot analyses of p-Erk1/2 (Figure 1C). While 
doxorubicin and miR-34a alone caused ~20% inhibition of 
p-Erk1/2 levels, triple-drug combination reduced p-Erk1/2 
to a comparable level as sorafenib alone, which might had 
reached a saturation point. Together, the results confirmed 
the independent actions of doxorubicin, sorafenib 
and miR-34a in 143B cells as well as the ultimate 
combinatorial effects.
Synergism of doxorubicin, sorafenib and miR-34a 
in the suppression of 143B cell proliferation
To define the combinatorial effects of doxorubicin, 
sorafenib and miR-34a in the inhibition of 143B cell 
growth, we employed CellTiter-Glo Luminescent Cell 
Viability Assay to quantitate the anti-proliferative 
activities of individual drugs and various combinations. 
As expected, doxorubicin, sorafenib and miR-34a prodrug 
alone reduced the proliferation of 143B cells in a dose-
dependent manner, and a dual- or triple-drug combination 
was more effective than individual agents (Figure 2A-2F). 
Interestingly, the anti-proliferation effects of sorafenib 
and miR-34a combination were mainly additive or even 
antagonistic at lower concentrations. In contrast, co-
administration of doxorubicin with sorafenib or miR-34a 
or sorafenib plus miR-34a produced synergistic effects 
in suppressing the proliferation of 143B cells, where 
the synergism of triple-drug combination persisted at 
all concentrations (Figure 2F). Therefore, combination 
therapy could offer remarkable degrees of dose reduction, 
especially for doxorubicin and miR-34a prodrug, to 
achieve the same levels of anti-proliferation effects 
(Supplementary Figure S1A-D). For instance, an 80% 
Figure 1: Independent and combined effects of triple drugs on DNA, mRNA and protein targets in highly metastatic 
osteosarcoma cells. A. Doxorubicin (Dox), bioengineered miR-34a prodrug (miR-34a) and sorafenib (Sor) were chosen as model drugs 
to target DNA and particular mRNAs and proteins, respectively. B. Immunofluorescent analysis of γH2A.X foci formation indicated Dox-
induced DNA damage in 143B cells, which were enhanced to greater degrees with the addition of miR-34a or Sor. Cells were fixed at 24 
h post-treatment and stained with specific γH2A.X antibody and then corresponding Alexa Fluor 488-conjugated antibody. Images were 
acquired with a confocal microscope. The bar indicates 20 µm. C. Immunoblot analysis of protein levels of p-Erk1/2 and c-Met confirmed 
the actions of Sor and miR-34a, respectively. Band density was determined by Image Lab software (Bio-Rad), and normalized to that of 
GAPDH. The protein levels in vehicle group were defined as 1.00.
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inhibition requires approximately 25 nM miR-34a alone or 
160 nM doxorubicin alone or 10,000 nM sorafenib alone, 
whereas only 4 nM miR-34a plus 40 nM doxorubicin 
and 4,000 nM sorafenib in the triple-drug combination 
(Figure 2A-D). Moreover, there was a stronger synergism 
and much greater extent of dose reduction for doxorubicin 
at higher degrees of cell inhibition (e.g., > 75%) when 
used with miR-34a or sorafenib or both, which would 
ultimately lessen or eradicate the risk of toxicity that might 
be induced by high doses of doxorubicin. 
Triple-drug combination with doxorubicin, 
sorafenib and miR-34a almost completely blocks 
the invasion potential of human 143B cells
We further performed in vitro cell invasion assays 
to determine the impact of triple-drug combination on 
invasion potential of 143B cells (Figure 2G-2H) since 
invasion abilities of cancer cells are critical for the local 
destruction and metastasis of tumors. Our results showed 
that miR-34a alone suppressed the invasion capability 
of 143B cells by about 50%, and doxorubicin plus 
sorafenib reduced cell invasion by 74%, as compared to 
the vehicle control. Furthermore, triple-drug combination 
with doxorubicin, sorafenib and miR-34a led to over 
90% suppression of cell invasiveness, a significantly 
greater degree than miR-34a prodrug or doxorubicin plus 
sorafenib (Figure 2H). The results demonstrate that triple-
drug combination was the most effective to block the 
invasion ability of highly metastatic 143B cells.
Triple-drug therapy suppresses orthotopic 
osteosarcoma xenograft tumor progression and 
spontaneous pulmonary metastases to the greatest 
levels in mouse models
We thus established an orthotopic osteosarcoma/
spontaneous metastases mouse model to determine the 
Figure 2: Doxorubicin, sorafenib and miR-34a produced synergism and the greatest effects in suppressing cancer cell 
proliferation and invasion. Dose-response curves for Dox and Sor A., Dox and miR-34a B., Sor and miR-34a C., and Dox plus Sor 
and miR-34a D., alone or in combination (Dox: Sor: miR-34a = 10:1000:1; thus the X-axis indicates the combined drug concentrations), 
in the inhibition of human osteosarcoma 143B cell proliferation. Cells were treated with various concentrations of Dox, Sor, and miR-
34a alone or in combination. Cell viability was determined using CellTiter-Glo luminescent cell viability assay at 72 h post-treatment. E. 
Estimated pharmacodynamic parameters for Dox, Sor and miR-34a in the suppression of 143B cell proliferation. Values are mean ± SD of 
quadruplicate treatments. F. Chou-Talalay (Fa-CI) plot demonstrated the synergistic effects for Dox, Sor and miR-34a in the suppression 
of 143B cell proliferation. G. and H. The invasion capability of 143B cells was inhibited to the greatest extent by the triple-drug treatment. 
72 h post-treatment, cells were subjected to Matrigel invasion assay for 30 h, fixed with 10% formalin, and then stained with 0.1% crystal 
violet. Images (G; 40 ×) were acquired with an Olympus IX2-UCB microscope, and invasion capabilities H. were compared for different 
treatments. Values are mean ± SD of triplicate treatments. **P < 0.01, and ***P < 0.001 (one-way ANOVA with Bonferroni post tests).
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effectiveness of rationally-designed triple-drug therapy in 
the suppression of xenograft tumor growth (Figure 3) and 
reduction of spontaneous pulmonary metastases (Figure 
4). The sizes of orthotopic xenograft osteosarcomas were 
monitored over time through bioluminescence imaging 
and by caliper. Our data showed that every drug treatment 
could significantly inhibit the outgrowth of viable 
xenograft osteosarcomas than vehicle control, albeit to 
different degrees, as manifested by bioluminescence 
intensities (Figure 3B) and calculated tumor volumes 
(Figure 3C). The degrees of suppression by triple-drug 
therapy were significantly greater than sorafenib plus 
either doxorubicin or miR-34a treatment (Figure 3C). 
Although statistical significance was not reached when 
triple-drug therapy group was compared to doxorubicin 
plus miR-34a treatment, the greatest extent of repression 
of osteosarcoma progression by triple therapy was obvious 
(Figure 3C). The consistent tendency was also indicated 
by visual inspection of dissected xenograft osteosarcomas 
(Figure 3D) and quantitative measurement (Figure 3E) of 
tumor weights.
To evaluate the effects of individual treatments 
on pulmonary metastases, lung tissues were dissected 
from all mice and GFP-expressing tumors were imaged. 
As demonstrated by ex vivo GFP signals including the 
distributions and intensities (Figure 4A), triple-drug 
combination therapy showed a much greater suppression 
of pulmonary metastases. We thus randomly selected four 
samples from each group for histopathological analyses, 
among which triple therapy group consistently showed 
Figure 3: Triple-drug therapy was the most effective in suppressing tumor growth in orthotopic, metastatic 
osteosarcoma xenograft mouse models. A. Scheme of therapy study in mouse models including osteosarcoma cell inoculation and 
drug treatment. B. Comparison of bioluminescent signals of orthotopic xenograft tumors on day 9, 23, and 30 among different treatment 
groups. C. Xenograft tumor growth was reduced to a significantly greater degree by triple therapy than vehicle or Dox, Sor, mir-34a alone, 
or Dox plus Sor, or Sor plus miR-34a (*P < 0.05, **P < 0.01, and ***P < 0.001 as compared to triple treatment; two-way ANOVA with 
Bonferroni post tests). D. Visual comparison of dissected orthotopic osteosarcoma tumor tissues from mice with different treatments. E. 
Weights of the dissected xenograft tumors (*P < 0.05, **P < 0.01, and ***P < 0.001; one-way ANOVA with Bonferroni post tests). Values 
are mean ± SD (N = 7 per group).
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the least lung metastases (Figure 4B). Specifically, the 
numbers of metastases per lung sample were much less in 
triple-drug therapy groups (1-4 foci of metastases in each 
lung) than vehicle control group (9-34 foci) (Figure 4C). 
In addition, the sum of the longest diameters of metastasis 
foci in triple-drug therapy group as well as doxorubicin/
miR-34a treatment group was significantly smaller 
than vehicle control (Figure 4D). Together, the results 
demonstrated that triple-drug therapy using doxorubicin, 
miR-34a and sorafenib provided the greatest degrees of 
protection against orthotopic osteosarcoma progression 
and pulmonary metastases. 
Triple-drug combination therapy is well tolerated 
in tumor-bearing mice
Following the first course of treatment (Figure 3A) 
mouse body weights decreased to different degrees, which 
was more obvious in doxorubicin-treated groups (Figure 
5A) and might indicate some doxorubicin-associated 
toxicity. However, all mice did not show any signs of stress 
such as hunched posture or labored movement. After five-
day recovery showing gain of body weights (Figure 5A), 
the second course of treatment was initiated with slightly 
reduced drug doses to avoid any potential adverse effects. 
After this treatment, all mice including those treated with 
vehicle showed 5-10% loss of body weights (Figure 5A), 
likely due to the progression of osteosarcoma (Figure 3), 
severe metastases burden (Figure 4) and/or handling rather 
than drug treatment. There was actually one mouse in the 
vehicle treatment group that showed the greatest degree 
of body weight loss at the last week of study, which was 
mainly attributable to cancer-associated cachexia resulting 
from advanced osteosarcoma.
To examine the risk of hepatic and renal toxicities, 
serum samples were collected and subjected to blood 
chemistry profiling (Figure 5B-5F). Levels of alanine 
Figure 4: Doxorubicin, sorafenib and miR-34a triple-drug therapy sharply reduced pulmonary metastases from 
orthotopic osteosarcomas in mouse models. A. Comparison of ex vivo GFP images of lung metastases between different treatment 
groups (N = 7 per group). B. H&E histology (40 ×) showed a much lower degree of tumor metastases (red arrow) for lung tissues dissected 
from mice under triple drug combination therapy. C. and D. Comparison of the numbers of lung metastases and sum of the longest 
diameters of lung metastases, respectively, between different treatments. The boxes extend from the 10th to the 90th percentile, the lines 
indicate the median values, and the whiskers indicate the range of values. *P < 0.05 as compared to vehicle control group (N = 4 per group).
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aminotransferase (ALT), aspartate aminotransferase 
(AST), total bilirubin, both blood urea nitrogen (BUN) and 
creatinine concentrations were all variable in individual 
treatment groups but within the normal ranges (except 
the cachectic mouse described above), the latter of which 
indicates the absence of liver and kidney toxicity. In 
addition, serum cardiac troponin I (cTnI) levels [33] were 
examined using an ELISA assay for the assessment of risk 
of doxorubicin-associated myocardial damage. Our data 
showed that cTnI levels in control and treatment groups 
were all under the lower limit of quantification (0.156 ng/
ml), suggesting the lack of cardiac toxicity. Together, these 
results indicated that therapeutic doses of doxorubicin, 
sorafenib and miR-34a prodrug alone or in combination 
were well tolerated in these mice.
Triple-drug combination therapy improves 
the overall survival to the greatest degree in 
experimental metastases mouse models
To further define the benefits of triple therapy for 
the treatment of late-stage metastases, we established 
an artificial pulmonary metastases mouse model via 
intravenous injection of 143B OS cells (Figure 6A). 
Metastases were confirmed to be visible on the surface of 
all mouse lung tissues at about 2 weeks post-inoculation 
in our pilot study. Therefore, we started the treatment 
with vehicle, miR-34a, doxorubicin/sorafenib, and the 
triple-drug combination on day 13 post-inoculation 
(Figure 6A). The survival study was terminated on day 
70 when all mice treated with vehicle or doxorubicin/
sorafenib died (Figure 6B). The presence of extensive 
pulmonary metastases after death or euthanasia was 
verified by necropsy and histological analyses (Figure 
6C). Furthermore, extrapulmonary metastases (e.g., skull, 
jaw, shoulder, knee or/and caudal vertebra) were noted in 
3 mice among each group treated with vehicle, miR-34a 
or doxorubicin plus sorafenib, in contrast to 2 mice treated 
with triple-drug combination.
While doxorubicin plus sorafenib therapy or miR-
34a alone significantly increased the overall survival 
and improved the median survival from 38 days to 54 
days, triple-drug combination therapy improved the 
overall survival to a more significant level and extended 
the median survival to an even longer time (60.5 days; 
Figure 5: Triple-drug combination therapy was well tolerated in mice. Compared to vehicle control group, systemic (co-)
administration of doxorubicin, sorafenib and bioengineered miR-34a prodrug had no significant impact on mouse body weights A. and 
blood chemistry profiles including alanine transaminase (ALT; B.), aspartate transaminase (AST; C.), total bilirubin D., blood urea nitrogen 
(BUN; E.), and creatinine F. levels. Values are mean ± SD (N = 5 in each group). The ranges of individual blood chemistry biomarkers 
(derived from BALB/c mice; Comparative Pathology Laboratory at UC-Davis) were marked as references. In addition, cTnI levels in all 
mice were below the lower limit of quantification (0.156 ng/ml), indicating the absence of cardiac toxicity.
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Figure 6B). In contrast to the death of all mice treated 
with vehicle control by day 56, 50% of the mice under 
triple-drug therapy were still alive on day 56 and 25% of 
mice were alive at the termination of the study (Figure 
6B) even though palpable pulmonary metastases were 
identified (Figure 6C). These results demonstrated that 
triple-drug therapy with DNA-intercalating doxorubicin, 
RNA-interfering miR-34a and protein kinase-inhibiting 
sorafenib could ultimately extend the survival.
DISCUSSION
Treating lethal metastasis might not be feasible 
through the inhibition of single target or pathway due to the 
presence of multiple and/or complementary mechanisms 
underlying complex cancer invasion-metastasis cascade 
[3]. In contrast, combination therapy has been proved as 
an effective means to fight against metastatic cancers [12]. 
Nevertheless, present combination therapies all focus on 
the co-inhibition of protein targets. For instance, the first 
immune checkpoint inhibitor combination approved by 
FDA in October, 2015 for the treatment of unresectable 
or metastatic BRAFV600 wild-type melanoma consists of 
nivolumab and ipilimumab, which target the programmed 
cell death protein 1 and cytotoxic T lymphocyte antigen 
4, respectively [34]. In this study, we demonstrated a new 
strategy to combat metastasis, which utilizes multiple 
drugs to co-target DNA, mRNA and protein molecules 
critical for many cellular processes. The benefits of 
“saturation attack” were strikingly obvious, given 
the greatest degrees in the suppression of orthotopic 
osteosarcoma progression and lung metastases, as well as 
improvement of survival in spontaneous and experimental 
metastases mouse models, which were attributable to the 
independent and complementary or combined actions of 
model drugs on DNA replication, mRNA translation, and 
protein signal transduction in cells. 
Doxorubicin, biological miR-34 prodrug, 
and sorafenib were chosen as model drugs to target 
DNA, RNA and protein molecules, respectively. The 
mechanistic actions of individual model drugs on DNA 
replication, target mRNA translation, and protein signal 
transduction were illustrated by an increased γH2A.X 
foci formation, reduced c-MET expression, and decreased 
Erk1/2 phosphorylation, respectively, in human OS 143B 
cells, which carry a p53 mutant and show high levels of 
p53 protein expression commonly identified in human 
malignant OS, thus representing a clinically-relevant OS 
cell model [35, 36]. While sorafenib or/and miR-34a alone 
had no or minimal effects on γH2A.X foci formation, both 
Figure 6: Triple-drug therapy improves overall survival to the greatest level in experimental lung metastases mice. 
A. Timeline of osteosarcoma cell inoculation to produce artificial pulmonary metastases mouse models, and drug treatment. B. Survival 
analysis showed that mice in treatment groups lived much longer than vehicle control (*P < 0.05, **P < 0.01; N = 7-8 per group; Log-rank 
(Mantel-Cox) Test). Median survival was 38 days for mice treated with vehicle, 54 days for miR-34a alone, 54 days for doxorubicin (Dox) 
plus sorafenib (Sor), and 60.5 days for doxorubicin, sorafenib plus miR-34a triple-drug therapy. C. H&E histology (40 ×) confirmed that 
mouse lungs were severely eroded by the tumor metastases (red arrow).
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could largely enhance doxorubicin-provoked DNA damage 
in 143B cells. By contrast, the reduction of pErk1/2 levels 
by sorafenib alone seemed to reach the maximal effects 
as the addition of doxorubicin and miR-34a did not show 
any impact. Consistent with the upregulation of c-MET in 
ovarian and hepatocellular carcinoma cells by doxorubicin 
and sorafenib that may be linked to drug resistance [37, 
38], our data revealed higher levels of c-MET in OS 
cells treated with doxorubicin and sorafenib, alone or in 
combination. However, the inclusion of c-MET mRNA-
targeting miR-34a completely erased such negative impact 
of doxorubicin and sorafenib, highlighting the benefits of 
independent and complementary actions of rationally-
combined DNA-intercalating, RNA-interfering, and 
protein-inhibiting drugs.
The strong synergism of doxorubicin, sorafenib 
and miR-34a allowed high degrees of dose reduction of 
individual drugs to achieve the same level of efficacy 
(e.g., Fa = 0.8). This is of particular important for 
chemotherapeutic doxorubicin and RNAi drug miR-34a, 
which at higher doses might induce cardiotoxicity and 
immune responses, respectively. As a result, relatively 
lower doses of individual drugs, alone or in combination, 
were utilized to evaluate saturation attack strategy in the 
mouse model of pulmonary metastases from orthotopic 
OS xenografts, which resembles the clinical features of 
human OS for the evaluation of new therapeutic strategies 
[3, 39]. Besides the body weight loss caused by severe 
tumor burden (vehicle control), drug-associated body 
weight loss was noted but acceptable in all treatment 
groups. Furthermore, the drug-/injection-induced body 
weight was restorable after withdrawal. All mice showed 
normal blood chemistry profiles, except for one mouse 
in the vehicle control group with cancer-related cachexia 
and abnormal blood BUN and creatinine levels, indicating 
that therapeutic doses of doxorubicin, sorafenib and 
bioengineered miR-34a prodrug were well tolerated in 
tumor-bearing mice without causing any liver or kidney 
toxicity. In addition, no mice showed any cardiac injury, 
as determined by the levels of cTnIs. This may be due to 
the use of much lower doses of doxorubicin in the present 
study, although it is unknown if co-administration of 
miR-34a prodrug would give rise to asymptomatic heart 
dysfunction of doxorubicin plus sorafenib [40]. 
The benefits of triple-drug therapy via co-targeting 
DNA, RNA and protein molecules were notably 
demonstrated by the greatest level of efficacy in the 
spontaneous metastases mouse models. Compared to 
vehicle control, single drug treatment offered a lower 
degree of suppression of orthotopic OS xenograft tumor 
growth and showed insignificant effects on pulmonary 
metastases. In addition to consistent findings on the 
effectiveness of doxorubicin chemotherapy plus miR-
34a replacement therapy on OS xenograft tumor growth 
[17], present study revealed much greater degrees of 
suppression by the combination of doxorubicin plus 
sorafenib, and sorafenib plus miR-34a than single drug 
treatment. Furthermore, co-administration of doxorubicin 
and miR-34a significantly suppressed lung metastases 
in these mice although the combinations of sorafenib 
plus miR-34a and doxorubicin plus sorafenib only had 
modest effects. Most importantly, the greatest degree of 
suppression of orthotopic OS xenograft tumor growth 
and pulmonary metastases were identified in mice treated 
with triple-drug combination. The optimal therapeutic 
outcomes from saturation attack observed in vivo are also 
consistent with the synergistic effects in the control of cell 
proliferation and the blockage of invasiveness identified 
in vitro. 
The present study further revealed the benefit of 
triple-drug therapy in experimental metastasis mouse 
model, as indicated by the extents of improvement 
of survival. Consistent with the encouraging results 
of doxorubicin plus sorafenib therapy for advanced 
HCC patients [40], dual-drug combination was able to 
significantly improve the survival of pulmonary metastatic 
mice. Furthermore, two cycles of monotherapy with 
bioengineered miR-34a prodrug significantly improved the 
survival rate of mice. This is in agreement with sufficient 
distribution of in vivo-jetPEI-encapsulated miR-34a 
prodrug to mouse lung tissues (unpublished data) and 
the actions of miR-34a on multiple therapeutic targets 
including PD-L1 implicated in immunotherapy [41, 42]. 
The triple-drug combination therapy enhanced mouse 
survival rate to the most significant level, which was also 
indicated by the longest median survival. The absence of 
statistical differences between triple-drug combination 
therapy and miR-34a alone or doxorubicin/sorafenib is 
likely due to a quite heavy burden of lung metastases 
in the experimental animal models and relatively small 
sample size in each group. 
In summary, we have demonstrated that a rational 
triple-drug combination therapy can offer robust and 
optimal outcomes in spontaneous and experimental 
metastases mouse models, as manifested by the 
greatest degrees of suppression of tumor progression 
and metastasis as well as extension of overall survival. 
Independent and combined actions of model drugs 
doxorubicin, miR-34a and sorafenib on the inhibition 
of DNA replication, RNA translation and protein signal 
transduction are indicated by the increase of γH2A.X, 
decrease of c-MET expression and reduction of ERK1/2 
phosphorylation, respectively. Although the identification 
of optimal dose regimens for direct clinical application 
will be challenging, rational combination therapy offers 
obvious synergism and permits the use of much lower and 
safe doses of drugs. Our findings suggest that co-targeting 
critical DNA, RNA and protein molecules may provide a 
framework for developing new strategies for the treatment 
of the deadliest metastases.
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MATERIALS AND METHODS
Materials
Doxorubicin (hydrochloride salt, > 99%) and 
sorafenib (p-toluenesulfonate salt, > 99%) were purchased 
from LC Laboratories (Woburn, MA, USA). RPMI 1640 
medium, trypsin and phosphate-buffered saline (PBS), 
fetal bovine serum, opti-MEM, BCA Protein Assay Kit, 
and Lipofectamine 3000 Transfection Kit were bought 
from Thermo-Fisher Scientific Inc (Waltham, MA, 
USA). RIPA buffer was bought from Sigma-Aldrich (St. 
Louis, MO, USA) and protease inhibitor cocktail was 
from Roche Diagnostics (Mannheim, Germany). Bovine 
Serum Albumin and in vivo-jetPEI were purchased from 
VWR (Visalia, CA, USA). ECL substrate and PVDF 
membrane were supplied by Bio-Rad (Hercules, CA, 
USA). Crystal violet was bought from MP Biomedicals, 
LLC (Solon, OH, USA). Manufacturers of antibodies used 
for western blot and immunofluorescence were shown in 
Supplementary Table S1. All other chemicals and organic 
solvents of analytical grade were purchased from Sigma-
Aldrich or Thermo-Fisher Scientific Inc.
Biologic miR-34a prodrug
Bioengineered miR-34a prodrug (tRNA/pre-miR-
34a) was expressed in E. coli (strain HST08) and purified 
by an anion exchange fast protein liquid chromatograph 
(FPLC) method, as described [13, 14, 43]. The purity 
of miR-34a prodrug was assessed by denaturing 
urea polyacrylamide gel electrophoresis (PAGE) and 
determined quantitatively by high performance liquid 
chromatography (HPLC) analysis [14]. Endotoxin 
activities were determined using the Pyrogent-5000 kinetic 
LAL assay (Lonza) by following the instructions. The 
miR-34a prodrugs over 98% pure and less than 10 EU/
µg RNA were used in the following study. Lipofectamine 
3000 and in vivo-jetPEI were used for the delivery of miR-
34a to cells and animals, respectively.
Human cell lines
The human OS cell lines 143B (CRL-8303) 
was bought from American Type Culture Collection 
(Manassas, VA, USA) and cultured in RPMI 1640 medium 
containing 10% FBS. The luciferase and GFP-expressing 
143B-GFP-Luc cells were generated after transduction 
with pCCLc-Luc-EGFP lentiviral constructs (Vector Core, 
UC Davis Medical center, Sacramento CA).
Cell viability assay, dose-response relationship 
and synergism
143B-GFP-Luc cells (5 × 103 cells/well) were 
seeded in 96-well plate overnight and then treated with 
different concentrations of doxorubicin (0, 5, 10, 20, 
50, 100, 200, 500 nM), sorafenib (0, 1, 2, 5, 10, 20, 50 
µM), miR-34a prodrug (0, 1, 2, 5, 10, 20, 50 nM) or 
the combination in fixed ratio (doxorubicin: sorafenib: 
miR-34a, 10:1000:1). After 72 hours, cell viability was 
determined by CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Madison, WI, USA). The degrees of 
inhibition were calculated by adjusting the vehicle control 
group to 0% and dose-response curves were established by 
plotting inhibition versus drug concentration. Cells were 
treated in quadruplicate and assayed separately. Data were 
fit to a normalized inhibitory dose-response model with 
variable slope (Y = 100/(1+10^((LogEC50-X)*HillSlope); 
GraphPad Prism, San Diego, CA) for the estimation of 
EC50, Hill slope, and Bottom values.
The Chou-Talalay approach [44] was employed to 
further analyze interactions of these three drugs in the 
inhibition of human OS 143B-GFP-Luc cell growth. For 
triple therapy, doxorubicin and sorafenib were used as an 
entirety to combine with miR-34a. The combination index 
(CI) values at each fraction affected (Fa) were calculated 
with CompuSyn software (ComboSyn, Inc., USA) to 
define the combinational effects, i.e., CI < 1 indicates 
synergism, CI = 1 indicates additivity, and CI > 1 indicates 
antagonism. In addition, the dose reduction index (DRI) 
values were calculated for the evaluation of dose reduction 
levels in combination therapy [44].
Invasion assay
Invasive potential of 143B-GFP-Luc cells, treated 
with vehicle, or 12 nM miR-34a, or 40 nM doxorubicin 
plus 4 µM sorafenib, or the combination for 72 h, was 
assessed as described previously [16, 17, 45] by using 
Corning BioCoat Matrigel Invasion Chamber with 8.0 
mm PET membrane coated with matrigel (Corning, NY, 
USA). Briefly, 5 × 104 cells in 500 µl serum-free RPMI 
1640 media were placed into the upper insert, and 750 
µl medium supplemented with 10% FBS was added into 
the well as a chemo-attractant. 30 h later, cells in the 
upper inserts were removed and the lower were fixed with 
10% formalin, stained with 0.1% crystal violet, and then 
photographed with five fields per insert under an Olympus 
IX2-UCB microscope (40 × magnifications). Each 
treatment group was conducted in triplicate and assessed 
independently. The quantification of invaded cells was 
calculated using Image J software and invasion capacity 
was determined by adjusting the vehicle control group to 
100%.
Oncotarget30752www.impactjournals.com/oncotarget
Immunofluorescence study on γH2A.X foci
143B-GFP-Luc Cells (1 × 105 per well) were plated 
into 6-well plates with coverslips on the bottom and then 
treated with vehicle, doxorubicin (40 nM), sorafenib (4 
µM) and miR-34a (12 nM) alone or in combination on 
the next day. 24 hours later, cells were fixed with 10% 
formaldehyde for 15 min at room temperature, rinsed 
three times in PBS, and blocked for 1 h in PBS consisting 
of 2% bovine serum albumin/0.3% Triton X-100 (Fisher 
Scientific) at room temperature. After rinsed three times 
in PBS, cells were incubated with anti-γH2A.X (Ser139) 
antibody (1:800, Cell Signaling Technology, Danvers, 
MA) overnight at 4 °C. After washed with PBS for 3 times, 
cells were incubated in Alexa Fluor® 488-conjugated goat 
anti-rabbit IgG (1:800, Cell Signaling Technology) for 1 h 
at room temperature in dark. Nucleus was counterstained 
with DAPI using Prolong® Gold Antifade Reagent (Cell 
Signaling Technology). Images were taken with a Zeiss 
Axio Observer.z1 Microscope coupled to a Zeiss LSM 710 
Scanning Device (Zeiss, Oberkochen, Germany).
Protein isolation and immunoblot analysis
Human OS 143B-GFP-Luc cells were treated with 
doxorubicin (40 nM), sorafenib (4 µM) and miR-34a (12 
nM) alone or in combination. Cells were collected at 72 
h post-treatment and lysed in RIPA buffer containing 
protease inhibitor cocktail. Following determination of 
protein concentrations with a BCA Protein Assay Kit, 
protein samples (30 µg/lane) were loaded and separated 
on a 10% SDS-PAGE gel and transferred onto PVDF 
membranes. Membranes were incubated with anti-c-MET 
(1:200; C-28; Santa Cruz, Dallas, Texas), anti-p-Erk1/2 
(1:1000; Thr202/Tyr204; Cell Signaling Technology), 
or anti-GAPDH (1:2,000; FL-335; Santa Cruz) rabbit 
antibody, and then with a peroxidase goat anti-rabbit IgG 
(Jackson ImmunoResearch Inc., West Grove, PA, USA). 
After incubation with Clarity Western ECL substrates 
(Bio-Rad, Hercules, CA, USA), the proteins were 
visualized with the ChemiDoc MP Imaging System (Bio-
Rad) and quantified by Image Lab software (Bio-Rad). 
GAPDH was used as a loading control.
Animal models and therapy studies
All animal procedures were approved by the 
Institutional Animal Care and Use Committee of 
University of California, Davis, and all animal studies 
were conducted in accordance with the relevant national 
and international guidelines. Non-obese diabetic/ severe 
combined immunodeficient (NOD/SCID) mice (NOD.
CB17-Prkdcscid/J) were purchased from Jackson 
Laboratory and adaptively fed at least one week before 
experiments. Animals were randomly assigned to 
treatment groups and closely monitored. Mice were 
euthanized if tumor size reached 2,000 mm3 (roughly 10% 
baseline body weight) or exceeded 2 cm in any direction, 
or body weight decreased 20%, otherwise, they were 
euthanized at the end of the study.
To establish orthotopic osteosarcoma xenograft/
spontaneous metastasis mouse models, 143B-GFP-
Luc cells (7.2 × 105 cells suspended in 40 µl PBS) were 
injected into the right tibia of anesthetized 7-week-old 
female mice [36, 46]. Tumor growth was monitored by 
bioluminescence imaging and measured with a caliper. In 
particular, tumor volume was calculated using the formula, 
tumor volume (mm3) = (length + width) × length × width × 
0.2618 [16, 36]. For bioluminescent imaging, D-luciferin 
(150 mg/kg) (BioVision, Inc. Milpitas, CA, USA) was 
injected into the abdominal cavity of anesthetized mice 
immediately before imaging. Images were acquired by 
KODAK Image Station 4000 Digital Imaging Systems and 
analyzed by Carestream Molecular Imaging Software 5.4.2 
(Carestream Health, Inc.). On day 11 after inoculation, 56 
mice were divided into 8 groups (7 mice in each group) 
according to the tumor volume and bioluminescent 
intensity to receive two cycles of treatments. The 1st cycle 
consisted of doxorubicin (12 µg/mouse, intravenously 
(IV), every other day (QOD) for 4 times), sorafenib (200 
µg/mouse, intragastrically (IG), every day (QD) for 7 
times), or/and miR-34a (12 µg/mouse, IV, QOD for 4 
times). The 2nd cycle consisted of doxorubicin (10 µg/
mouse, IV, QOD for 4 times), sorafenib (200 µg/mouse, 
IG, QOD for 4 times) or/and miR-34a (10 µg/mouse, IV, 
QOD for 4 times). At the end of the study, all mice were 
sacrificed and tumors were dissected and weighed. The 
lung tissues were dissected for ex vivo GFP imaging and 
fixed in 10% formalin, and then subjected to hematoxylin 
and eosin (H&E) staining for histological evaluation in 
the Clinical Immunohistochemistry Laboratory at Roswell 
Park Cancer Institute (Buffalo, NY, USA). Additionally, 
serum was isolated using a serum separator (BD 
Biosciences, San Jose, CA, USA) and then subjected to 
blood chemistry profiling in the Comparative Pathology 
Laboratory at UC Davis. Serum cardiac troponin-I (cTnI) 
was analyzed with a Mouse Cardiac Troponin-I ELISA Kit 
(Life diagnostics, Inc. West Chester, PA, USA).
To establish artificial metastasis mouse models for 
survival study, 9-week-old female mice were inoculated 
with 5 × 106 143B-GFP-Luc cells in 250 µl PBS per 
mouse via the tail vein injection. 12 days later, the mice 
were randomized to 4 groups to receive two cycles of miR-
34a, doxorubicin/sorafenib, doxorubicin/sorafenib+miR-
34a or control vehicle treatment. The 1st cycle consisted 
of doxorubicin (12 µg/mouse, IV, QOD for 6 times), 
sorafenib (200 µg/mouse, IG, QD for 10 times), or/and 
miR-34a (12 µg/mouse, IV, QOD for 6 times). The 2nd 
cycle consisted of doxorubicin (10 µg/mouse, IV, QOD for 
8 times), sorafenib (200 µg/mouse, IG, QOD for 8 times) 
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or/and miR-34a (10 µg/mouse, IV, QOD for 8 times). 
Body weight loss over 10% was considered as death. All 
mice underwent complete necropsy for the confirmation 
of experimental pulmonary metastases. Survival was 
analyzed by Kaplan-Meier method and compared by Log-
rank (Mantel-Cox) Test (GraphPad Prism).
Statistics analysis
Statistical analysis was performed using GraphPad 
Prism. Depending upon the groups and variances, data 
were analyzed with one-way or two-way ANOVA. 
Additionally, Bonferroni post-tests were applied for 
multiple comparisons. Difference was considered as 
statistically significant at the level of P < 0.05.
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